Vaxcyte, Inc. — Director's Dealing 2023

Nov 9, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2023-11-09

Reporting Person: Paya Carlos V (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-11-09	Common Stock	G	3125	$0.00	Disposed	2500	Direct
2023-11-09	Common Stock	A	3125	$0.00	Acquired	3125	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-11-09	Stock Option (right to buy)	$22.02	G	30000	Disposed	2031-10-26	Common Stock (30000)	Direct
2023-11-09	Stock Option (right to buy)	$22.02	G	30000	Acquired	2031-10-26	Common Stock (30000)	Indirect
2023-11-09	Stock Option (right to buy)	$22.70	G	18750	Disposed	2032-05-31	Common Stock (18750)	Direct
2023-11-09	Stock Option (right to buy)	$22.70	G	18750	Acquired	2032-05-31	Common Stock (18750)	Indirect
2023-11-09	Stock Option (right to buy)	$53.08	G	15000	Disposed	2033-06-12	Common Stock (15000)	Direct
2023-11-09	Stock Option (right to buy)	$53.08	G	15000	Acquired	2033-06-12	Common Stock (15000)	Indirect

Footnotes

F1: The reported transactions involve the Reporting Person's transfer of certain securities to a trust for the sole benefit of the Reporting Person.

F2: As previously disclosed in Reporting Person's Form 4 filed on June 15, 2023, this represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 13, 2024 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.

F3: Shares are held directly by a trust for the sole benefit of the Reporting Person.

F4: Option vests over 36 months, 1/3 of which will vest on October 27, 2022 and 1/36 of which will vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date.

F5: Options are held directly by a trust for the sole benefit of the Reporting Person.

F6: The shares of Common Stock subject to the option vested fully on June 1, 2023.

F7: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 13, 2024 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.